Mycoprotein and Pea Protein Blend and Muscle Protein Synthetic Response
BPM
Comparing Postprandial Muscle Protein Synthesis Rates Following the Consumption of Mycoprotein, Pea Protein and a Mycoprotein/Pea Protein Blend in Resistance Trained Individuals
1 other identifier
interventional
33
1 country
1
Brief Summary
Dietary protein is vital for the preservation of health and optimal adaptation to training. Plant proteins are considered inferior to animal proteins with respect to their ability to stimulate an acute muscle building response and therefore support long-term muscle reconditioning. Pea protein is a highly commercially available plant proteins source (available as supplements, food ingredients etc.), yet there is no research investigating its ability to stimulate a muscle building response. The investigators aim to assess the effect of consuming pea protein on muscle protein synthesis rates and compare these results to mycoprotein, a source known to elicit a robust anabolic response. Pea protein is lower in some of the essential amino acids, namely methionine, which could mean it is less effective compared with mycoprotein which has a more complete amino acid profile. So in addition to comparing pea with mycoprotein, the investigators also want to compare to a blend of pea and mycoprotein to see if replenishing the amino acid content in pea 'rescues' the anabolic response.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2021
CompletedFirst Submitted
Initial submission to the registry
May 5, 2021
CompletedFirst Posted
Study publicly available on registry
May 20, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 15, 2022
CompletedMarch 22, 2023
March 1, 2023
1.1 years
May 5, 2021
March 21, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Muscle protein synthesis
The rate of synthesis of new muscle protein (Fractional synthetic rate %/h)
8.5 hours
Secondary Outcomes (4)
Plasma amino acid kinetics
8.5 hours
Serum insulin concentrations
8.5 hours
Translocation of mTOR via immunohistochemistry
8.5 hours
mTOR phosphorylation via ATP kinase assay
8.5 hours
Study Arms (3)
Mycoprotein
EXPERIMENTALBolus ingestion of mycoprotein providing 25g of protein.
Pea protein
EXPERIMENTALBolus ingestion of pea protein providing 25g of protein.
Mycoprotein/pea protein dry blend
EXPERIMENTALBolus ingestion of mycoprotein/pea protein dry blend providing 25g of protein.
Interventions
Ingestion of 25g of protein
Eligibility Criteria
You may qualify if:
- BMI between 18 and 30
- Resistance trained
You may not qualify if:
- Any metabolic impairment
- Smoking
- Use of over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices).
- A personal family history of epilepsy, seizures or schizophrenia.
- Allergic to Quorn/mycoprotein/edible fungi/environmental mould products.
- Any motor disorder.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Exeterlead
- Quorncollaborator
Study Sites (1)
University of Exeter
Exeter, United Kingdom
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 5, 2021
First Posted
May 20, 2021
Study Start
May 1, 2021
Primary Completion
June 15, 2022
Study Completion
June 15, 2022
Last Updated
March 22, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share